Dashboard
Manage Tickers

ACET


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-adicet-bio-raises-price-target-to-9
HC Wainwright & Co. Maintains Buy on Adice...
11/07/2025 12:38:50

HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from ...

adicet-bio-q3-eps-029-beats-030-estimate
Adicet Bio Q3 EPS $(0.29) Beats $(0.30) Es...
11/05/2025 22:09:27

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
11/04/2025 21:06:29

adicet-bio-doses-first-patient-in-phase-1-trial-of-adi-001-for-treatment-refractory-rheumatoid-arthritis
Adicet Bio Doses First Patient In Phase 1 ...
10/16/2025 11:06:22

guggenheim-maintains-buy-on-adicet-bio-raises-price-target-to-8
Guggenheim Maintains Buy on Adicet Bio, Ra...
10/08/2025 12:29:18

Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $7 to $8.

adicet-bios-lupus-trial-delivers-100-response-setting-stage-for-phase-2
Adicet Bio's Lupus Trial Delivers 100% Res...
10/07/2025 15:05:59

Adicet Bio reported strong Phase 1 lupus trial results with ADI-001, showing 100% response in nephritis patients and raising $8...

adicet-bio-priced-registered-direct-offering-of-70m-shares-at-1share-and-pre-funded-warrants-to-purchase-10m-shares-at-09999-per-pre-funded-warrant-with-gross-proceeds-of-approximately-80m
Adicet Bio Priced Registered Direct Offeri...
10/07/2025 11:03:58

adicet-bio-shares-initial-safety-and-efficacy-data-from-the-first-seven-patients-dosed-with-adi-001-in-the-ongoing-phase-1-study-in-patients-with-autoimmune-diseases
Adicet Bio Shares Initial Safety And Effic...
10/07/2025 10:51:49

Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, o...

guggenheim-reiterates-buy-on-adicet-bio-maintains-7-price-target
Guggenheim Reiterates Buy on Adicet Bio, M...
09/19/2025 12:45:28

Guggenheim analyst Yatin Suneja reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $7 price target.

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/19/2025 21:06:03

adicet-bio-q2-eps-034-misses-030-estimate
Adicet Bio Q2 EPS $(0.34) Misses $(0.30) E...
08/07/2025 20:46:49

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) ...

adicet-bio-doses-first-systemic-sclerosis-patient-in-phase-1-clinical-trial-of-adi-001
Adicet Bio Doses First Systemic Sclerosis ...
07/24/2025 11:09:16

hc-wainwright--co-assumes-adicet-bio-at-buy-announces-price-target-of-4
HC Wainwright & Co. Assumes Adicet Bio at ...
07/23/2025 10:40:51

HC Wainwright & Co. analyst Robert Burns assumes Adicet Bio (NASDAQ:ACET) with a Buy rating and announces Price Target o...

why-block-shares-are-trading-higher-by-10-here-are-20-stocks-moving-premarket
Why Block Shares Are Trading Higher By 10%...
07/21/2025 10:04:54

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
05/09/2025 12:10:06

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/08/2025 21:05:48

adicet-bio-q1-eps-031-beats-034-estimate
Adicet Bio Q1 EPS $(0.31) Beats $(0.34) Es...
05/06/2025 20:38:44

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.34) by...

adicet-bio-to-give-oral-presentation-for-its-preclinical-adi-270-data-at-the-american-society-of-gene-and-cell-therapy-28th-annual-meeting
Adicet Bio To Give Oral Presentation For I...
04/28/2025 20:34:10

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
04/17/2025 21:05:38

guggenheim-reiterates-buy-on-adicet-bio-maintains-7-price-target
Guggenheim Reiterates Buy on Adicet Bio, M...
03/21/2025 14:04:18

Guggenheim analyst Yatin Suneja reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $7 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION